Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the company’s change in strategy, opting to have enhanced direct presence in the region. Moreover, he explains why Boston Scientific’s therapies are uniquely positioned to help more patients in the MENA region and how recent decisions like the acquisition of UK-based BTG will further boost their commercial success.
In order to achieve sustained double-digit growth, we need to invest in training, education, awareness and work hand in hand with physicians to identify the right patients for the right therapies
